NCT04208386 is a Phase 1 clinical trial of JNJ-73763989 in Hepatic Impairment, sponsored by Janssen Sciences Ireland UC.

Who is sponsoring NCT04208386?

NCT04208386 is sponsored by Janssen Sciences Ireland UC.

What drugs are being tested in NCT04208386?

Interventions in NCT04208386: JNJ-73763989.

What condition does NCT04208386 study?

NCT04208386 studies Hepatic Impairment.

Is NCT04208386 still recruiting?

NCT04208386 is currently completed. Last updated 30 September 2020.

Last reviewed 2020-09-30 · How we verify

NCT04208386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Completed Phase 1 Last updated 30 September 2020

What this trial tests

Phase 1 trial testing JNJ-73763989 in Hepatic Impairment in 16 participants. Completed in 20 July 2020.

Timeline

8 January 2020

Primary endpoint
20 July 2020

20 July 2020

Quick facts

Lead sponsor	Janssen Sciences Ireland UC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	8 January 2020
Primary completion	20 July 2020
Estimated completion	20 July 2020
Sites	1 location across Germany

Drugs / interventions tested

JNJ-73763989 — full drug profile →

Conditions studied

Hepatic Impairment — all drugs for Hepatic Impairment →

Sponsor

Janssen Sciences Ireland UC — full company profile →

Who can join

Adults 18 to 75, any sex, with Hepatic Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the single-dose pharmacokinetic (PK) of JNJ-73763976 and JNJ-73763924 following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in participants with liver cirrhosis and various degrees of impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Paving the Road for RNA Therapeutics.
Dammes N, Peer D. · · 2020 · cited 159× · PMID 32893005 · DOI 10.1016/j.tips.2020.08.004
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.
Liu M, Wang Y, Zhang Y, Hu D, et al · · 2025 · cited 62× · PMID 40059188 · DOI 10.1038/s41392-024-02112-8
New Approaches to the Treatment of Chronic Hepatitis B.
Alexopoulou A, Vasilieva L, Karayiannis P. · · 2020 · cited 50× · PMID 33019573 · DOI 10.3390/jcm9103187
Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor.
Ramírez-Cortés F, Ménová P. · · 2025 · cited 22× · PMID 39628900 · DOI 10.1039/d4md00652f
Recent Update on siRNA Therapeutics.
Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, et al · · 2025 · cited 19× · PMID 40331977 · DOI 10.3390/ijms26083456

Verify or expand the search:

Other trials of JNJ-73763989

Trials testing the same drug.

NCT05275023 — An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death P · Phase 2 · completed
NCT05123599 — A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBe · Phase 1 · completed
NCT05005507 — A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis · Phase 2 · terminated
NCT04963738 — A Study of JNJ-73763989 in Adult Participants With Renal Impairment · Phase 1 · completed
NCT04585789 — A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus · Phase 2 · completed

Other recruiting trials for Hepatic Impairment

Currently open trials in the same condition.

NCT07269301 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function · Phase 1 · recruiting
NCT07219550 — A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) · Phase 1 · recruiting
NCT07144111 — A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib · Phase 1 · recruiting
NCT07023354 — A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems · Phase 1 · recruiting
NCT06985615 — A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement · Phase 1 · recruiting

Other Janssen Sciences Ireland UC trials

Trials by the same sponsor.

NCT04208399 — A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 · Phase 1 · completed
NCT04056611 — Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who A · Phase 2 · terminated
NCT04129554 — A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virolo · Phase 2 · completed
NCT03982186 — A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepati · Phase 2 · completed
NCT04002752 — A Study of JNJ-73763989 in Healthy Japanese Adult Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04208386 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Sciences Ireland UC
Last refreshed: 30 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04208386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing